Tim Goodnow

President and Chief Executive Officer, Senseonics Holdings, Inc.

Search every verified Tim Goodnow interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Timothy Goodnow, President and CEO of Senseonics Holdings, discussed the company's implantable continuous glucose monitoring (CGM) system, Eversense, in interviews from 2018 and 2021. He described the device as providing glucose readings every five minutes and enabling users to track trends and anticipate hyper- or hypoglycemia. Goodnow stated that Senseonics was developing a sensor lasting 365 days, with a goal of reducing fingerstick calibration to once a week, while emphasizing that the company would not compromise on accuracy. He also noted the company's work with private insurers to expand coverage in the United States and mentioned a coverage agreement with Aetna in 2018. In the 2021 interview, Goodnow highlighted the use of contact lens material on the sensor surface and the ongoing development of the 365-day product. He referenced the role of the company's chief medical officer, Dr. Fran Kaufman, in training healthcare professionals on the insertion procedure. Goodnow also discussed the expansion of the insertion network in Europe, where the sensor was approved for up to 180 days, and the company's plans to bring that version to the U.S. market. He described the value of the implantable system as enabling patients to "put it under the skin and forget about it," aiming to simplify long-term diabetes management.